#USA #Garden City #Encelto #OCLI Vision #MacTel

ENCELTO Therapy Revolutionizes Treatment for MacTel

On September 22, 2025, OCLI Vision achieved a remarkable milestone in the field of ophthalmology by performing the first ENCELTO gene therapy procedure in the Northeastern United States. This innovative treatment is designed for patients suffering from Macular Telangiectasia Type 2, commonly known as MacTel, a rare and debilitating neurodegenerative condition that leads to progressive vision loss.

What is MacTel?

MacTel is a condition that primarily affects the macula, the central part of the retina responsible for sharp, detailed vision. It is characterized by the abnormal growth of blood vessels, leading to deterioration of photoreceptors in the retina. Traditionally, treatment options for MacTel have been limited, often leaving patients with little hope and a “watchful waiting” approach that fails to address the progressive decline in vision.

Breakthrough with ENCELTO

The ENCELTO procedure signifies a breakthrough in the management of this previously untreatable disease. Dr. Deepika Malik, the vitreoretinal surgeon who led the operation at OCLI Vision, expressed her enthusiasm for this advancement, stating, "This upcoming procedure represented a major step forward in how we treat MacTel, offering hope where only irreversible decline had been possible."

ENCELTO is the first cell-based gene therapy approved for MacTel patients, employing an innovative approach that involves surgical implantation of encapsulated cells engineered to release ciliary neurotrophic factor (CNTF) directly into the retina. This therapeutic protein is crucial for maintaining the health of photoreceptors, ultimately helping to preserve vision and improve life quality for afflicted patients.

How ENCELTO Works

The mechanism of ENCELTO centers on an implanted device that continuously delivers CNTF. This sustained release is vital for counteracting the damaging effects of MacTel, facilitating improved photoreceptor functionality and overall retinal health. Previous treatment methods lacked the capacity to directly influence the disease's progression, making ENCELTO a groundbreaking option for many patients.

Significance of OCLI Vision's Role

OCLI Vision was chosen as the first clinic in the Northeast and the second in the world to perform this procedure, highlighting their expertise in treating retinal diseases. Tom Burke, CEO of Spectrum Vision Partners, remarked, "This milestone reflected our mission to expand access to innovative therapies across our network. OCLI Vision's leadership in introducing ENCELTO emphasizes the commitment to providing high-quality patient care and improved outcomes."

The successful implementation of ENCELTO not only paves the way for enhanced treatment options but also showcases the dedication of OCLI Vision’s medical team and the potential to positively impact numerous patients suffering from MacTel.

Looking Forward

As OCLI Vision continues to forge ahead with new treatments like ENCELTO, the future appears promising for patients with MacTel. The successful execution of this procedure marks a pivotal moment in ophthalmology, offering new hope to those affected by a disease that once seemed lead to inevitable vision loss. With ongoing advancements in medical technology and continued investment in patient care, the prospects for MacTel patients are brighter than ever.

For further information about OCLI Vision and their specialized eye care services, visit OCLI Vision's official website.

About OCLI Vision

Founded in 1997, OCLI Vision stands as a leading ophthalmology practice in the United States, providing comprehensive eye care services throughout New York, New Jersey, Connecticut, Pennsylvania, and West Virginia. With a talented team of ophthalmologists and optometrists across various specialties, OCLI Vision is dedicated to improving patient outcomes through innovative treatment solutions.